1.28
-0.01(-0.78%)
Currency In USD
| Previous Close | 1.29 |
| Open | 1.28 |
| Day High | 1.32 |
| Day Low | 1.26 |
| 52-Week High | 7.5 |
| 52-Week Low | 1.22 |
| Volume | 551,281 |
| Average Volume | 1.7M |
| Market Cap | 76.16M |
| PE | -0.57 |
| EPS | -2.25 |
| Moving Average 50 Days | 1.72 |
| Moving Average 200 Days | 2.09 |
| Change | -0.01 |
If you invested $1000 in Biomea Fusion, Inc. (BMEA) since IPO date, it would be worth $68.82 as of November 14, 2025 at a share price of $1.28. Whereas If you bought $1000 worth of Biomea Fusion, Inc. (BMEA) shares 3 years ago, it would be worth $160.6 as of November 14, 2025 at a share price of $1.28.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biomea Fusion to Participate at Jefferies London Healthcare Conference
GlobeNewswire Inc.
Nov 10, 2025 12:00 PM GMT
SAN CARLOS, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it is scheduled to participate in a firesid
Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025
GlobeNewswire Inc.
Nov 05, 2025 12:00 PM GMT
The Company’s investigational small molecule glucagon-like peptide-1 (“GLP-1”) receptor agonist (“RA”), BMF-650, demonstrated potent weight loss and good tolerability in obese cynomolgus monkeys A Phase I study of BMF-650 in healthy obese patients is
Biomea Fusion to Present Poster Presentations at ObesityWeek®2025
GlobeNewswire Inc.
Oct 30, 2025 12:00 PM GMT
SAN CARLOS, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that it will present poster presentations at ObesityWeek® 2025, taking pla